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ABSTRACT
Aging is a multi-factorial process, where epigenetic
factors play one of the major roles in declines of gene
expression and organic function. DNA methylation
at CpG islands of promoters can directly change the
expression of the neighbouring gene mostly through
inhibition. Furthermore, it is known that DNA methylation
patterns change during aging. In our study, we
investigated gene regulation through DNA methylation
of genes up- and downregulated in long-lived people
compared to a younger cohort. Our data revealed that
comparatively highly methylated genes were associated
with high expression in long-lived people (e.g. over 85).
Genes with lower levels of methylation were associated
with low expression. These findings might contradict
the general model used to associate methylation status
with expression. Indeed, we found that methylation
in the promoter regions of all investigated genes is
rather constant across different age groups, meaning
that the disparity between methylation and expression
only happens in older people. A potential explanation
could be the impact of other epigenetic mechanisms,
possibly related to stress.
KEYWORDS
Longevity; DNA methylation; gene expression;
epigenetics; CpG islands, CpG sites; aging
INTRODUCTION
With aging comes a loss of cognitive abilities,
reduction of organ function, and a rapidly increasing
risk of chronic diseases such as Alzheimer’s type of
dementia, diabetes and cancer [1]. Two-thirds of deaths
worldwide can be attributed to age-related diseases [2,
3]. Over the course of human evolution, life expectancy
has risen dramatically alongside diseases associated
with age [4, 5]. Maintaining health in a long-living
population can powerfully benefit from understanding
the mechanisms that protect older people from these
diseases, for example by investigating those who have
reached 90 years or older without suffering from major
impairments [2, 6]. Despite extensive studies in
areas of genetics, transcriptomics and epigenetics, the
secret of long-lived healthy human individuals is still
unknown [7, 8]. It is, however, widely accepted that
this phenotype is a result of a combination of genetic,
epigenetic and environmental factors. A number of
twin studies have shown that genetic factors make a
significant contribution [9–11]. Recently, this has led
to large-scale studies attempting to associate genetic
variation with longevity [2, 12, 13]. However, so far only
three loci significantly associated with human longevity
or healthy human aging have been identified, genetic
variations on APOE, FOXO3A and 5q3.33 [2, 14–16].
The APOE ε4 allele, representing a risk factor for
Alzheimer’s disease, has been found to be less frequent
in centenarians compared to younger controls [17]. The
Single Nucleotide Polymorphism (SNP) rs2149954 on
chromosome 5q3.33 has shown to be associated with
lower all-cause mortality in long-lived individuals [14, 18,
19].
More is known about the relationship between gene
expression and longevity. A widely accepted assumption
in literature is that long-lived people have a better
tolerance against stress, (age-related) diseases and
other negative influences. The phenomenon is also
known as resilience. Certain genes can affect lifespan
and the quality of health [20–22]. A hypothesis is
that these genes may have a higher expression in
such individuals than in those who die at an average
age. However, little is still known about the way most
of these genes are regulated. One level at which
genes can be regulated directly is DNA methylation,
an epigenetic mechanism [23] involving the binding
of methyl groups predominantly to cytosine bases in
DNA. Regions of DNA that are at least 200 kb in
length in which adjacent C and G bases make up more
than 50 % of the sequence are called CpG islands
(CGIs) [6, 24, 25]. DNA methylation in CpG islands
of promoter regions is known to impair the expression
of the neighbouring gene [25, 26]. Epigenetic features
beyond DNA methylation are known to change with
age through environmental influences [27]. As the
environment has the largest impact on lifespan [9–
11], epigenetics may play an important role in aging
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and longevity. It is indeed already known that DNA
undergoes a global hypomethylation through the whole
life span, but site-specific examples of hypermethylation
are also found, particularly in CGIs [28–30].
A large-scale eQTL study by Häsler et al. 2017
compared the expression profiles of long-lived
individuals (LLIs, aged 90-104 years) and a younger
control group (aged 20-55), identifying 6075 differently
expressed genes in whole blood samples [31]. In our
study, we analyzed the gene expression data from
Häsler and colleagues [31] in combination with DNA
methylation data from the public database NCBI to
gain new insights into the epigenetic regulation of
gene expression over the course of aging. The more
specific aims were to determine whether and how DNA
methylation influences the up- and downregulation of
these genes, to uncover differences in DNA methylation
between the groups of genes whose expression was
affected in opposite ways, and to compare the DNA
methylation status of these genes in young (aged 19-45)
and very old (aged 85-101) individuals.
DATA
A summary of all data that will be discussed within
the following paragraph is provided in Supplementary
Information Table S1.
Gene expression data
The raw RNA-seq data investigated in this paper were
taken from the study by Häsler et al. (2017) [31].
Häsler and colleagues compared the gene expression
profiles of LLIs (aged 90-104, n = 55) to those of
younger controls (aged 20-55, n = 73) and identified
6075 genes in whole blood whose levels of expression
were significantly different. In our study, we re-analyzed
the gene expression analysis of this paper getting all
differentially expressed genes of young and old (see
Methods). For more descriptive results, we later used
the 25 most significant genes whose expression was
upregulated and 25 which were downregulated in the
LLIs compared to controls of the 6075 genes of the eQTL
study; for the full list of these 50 genes, see Table S1 in
the study of Häsler et al. (2017).
DNA methylation data
Methylation data were obtained from a study of aging
in which methylome profiles were generated from the
whole blood of 656 individuals whose ages ranged
widely (from 19-101 years) [32]. Methylation detection
in the study was carried out using the Illumina Infinium
450k Human DNA methylation Bead chip; the analysis
yielded methylation states for more than 450.000 CpG
sites spread over the whole genome [33]. The
methylation status of a specific CpG site was calculated
by the ratio of the number of methylated sites compared
to the total combined number of both methylated and
unmethylated sites. The values assigned to sites
were represented between 0 (unmethylated) and 1
(methylated). The choice of the dataset was based
on the wide range of ages of individuals in the study,
including long-lived individuals with an age over 85
years (n = 53), which allowed us studying expression
methylation correlation from similar age groups. The
methylation data used in the study are available in the




The differentially expressed genes (DEG) were
determined using R. DESeq2 was used to determine
size factors and normalize the data. As our sample
size was large and the memory management of regular
tools not handy for this kind of dataset, we performed a
Wilcoxon rank-sum test on normalized data followed by
multiple testing correction using the Hochberg method.
The output revealed 3088 DEG; with 1345 up- and
1743 downregulated genes in LLIs. In the following,
we will use the definition “all DEG” for the DEG we
have calculated on our own (subset 1). The 25
most significant upregulated and the 25 most significant
downregulated genes were retrieved from the short-list
by Häsler and colleagues [31](subset 2). A further
subset (subset 3) containing all genes of the whole
genome was used as reference comparison.
Selection of genomic regions, promoters and CpGs
The promoter regions of all three subsets were
identified via the publicly available UCSC Genome
Website “Table Browser“ [34, 35]. The length of the
promoter regions was defined as 2000 bp upstream
and 500 bp downstream of the transcription start-site of
each gene. The length of promoter regions was also
tested in subsequent analysis of DNA methylation and
-2000, +500 were selected as reasonable values; see
Supplementary Information Figure 1. Subsequently, we
searched for CGIs for all filtered promoter regions (using
Table Browser from the UCSC website) and the CpG
sites within the CGIs were extracted as IDs. 15 of the 25
upregulated genes had at least one CGI in the promoter
region, whereas among the 25 downregulated genes
16 genes showed this mark (Table 1). We present a
summary of the genes with CGIs in the promoter region
for all subsets in the Supplementary Information Table
S2.
Statistical analysis
R was used for all statistical analysis steps.
To compare the average methylation status of the
upregulated and the downregulated genes in each
individual of both gene subsets as well as for the whole
genome, a t-test was performed, using a significance
level of 0.05.
To explore functionality of gene regulation, we then
focused on the 25 most up- and downregulated
genes. We used ordinary linear regression analysis to
investigate the extent of potential relationships between
2
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Table 1: Upregulated and downregulated genes with CGIs in the promoter region; including the regression coefficient, R2 and
p-value for the average methylation status and the age. Coefficient values are grouped into either positive or negative coefficients
and sorted in descending order by the amount of the value. Gray-deposited genes do not show a significant coefficient.
Upregulated genes Coefficient R2 p-value
All genes 4.3417E-05 0.02737276 2.055E-05
POLB -0.00011529 0.02729836 2.11E-05
SLC27A3 -9.90E-05 0.01829921 0.0005126
TRIP4 -6.61E-05 0.01296809 0.0034932
DNAJC1 -3.90E-05 0.01876343 0.0004343
DES 0.00087522 0.16070207 1.02E-26
MANEAL 0.00012929 0.03074176 6.27E-06
PHLDA3 0.00012286 0.04521801 3.82E-08
PAQR4 9.33E-05 0.00965713 0.01179377
HOXB7 5.55E-05 0.03074771 6.25E-06
VAMP5 0.00017412 0.00215643 0.2349325
LINC00899 -1.65E-05 0.000367 0.624
PSMB8 5.12E-06 0.00014719 0.7564415
SAP30 -3.09E-06 5.79E-05 0.84576
RIPK3 3.02E-06 1.49E-05 0.9212891
Downregulated genes Coefficient R2 p-value
All genes 5.6911E-05 0.0409773 1.704E-07
RASGRF2 0.00021243 0.04510329 3.98E-08
NELL2 0.0002086 0.1065761 9.35E-18
SFRP5 0.00016533 0.06150759 1.19E-10
NT5E 0.00014536 0.03180103 4.31E-06
RCAN3 0.00012215 0.05495721 1.22E-09
N4BP3 7.34E-05 0.01189972 0.0051582
CACHD1 7.28E-05 0.01976716 0.0003037
CAMK4 5.73E-05 0.03248401 3.39E-06
ZFYVE9 4.55E-05 0.00746807 0.0268769
NIPAL3 -0.00041598 0.05202189 3.45E-09
AQP3 4.01E-05 0.005764 0.0519
NOG 6.13E-05 0.00451352 0.0855455
SPTBN1 2.80E-05 0.003919 0.1091766
GPRASP1 9.24E-07 0.001188 0.378
CD248 -7.38E-05 0.00118756 0.3782035
SERPINE2 0.00012215 5.61E-06 0.9517
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age and the mean methylation status of promoters
for both groups of genes. The explanatory variable
corresponds to the age and the average methylation
status represents the dependent variable. A summary
table of the linear regression analysis for all DEG can be
found in the Supplementary Information Table S4.
RESULTS
Age-related upregulation of gene expression is
associated with a higher methylation status
First, we investigated whether there is a difference in
the overall methylation status between the upregulated
and the downregulated genes. We compared the
average methylation status of both subsets within the
promoters with that of the whole genome. The
average methylation status of the upregulated genes
was significantly higher than the methylation status of the
downregulated genes in both gene groups (meanup25
= 0.1122 vs. meandown25 = 0.0694, meanupall =
0.0814 vs. meandownall = 0.0726, p < 2.2 x 10−16
; Figure 1, Supplementary Information Table S3).
The 25 upregulated genes together yield nearly the
same mean value for the methylation status as that of
the whole genome (meanGenome = 0.1127, Figure 1,
Supplementary Information Table S3). A t-test between
the genome and the 25 upregulated genes verified the
similarity of the average methylation status with p-value
= 0.141. In blood cells, our analysis revealed an average
methylation status with a value close to 0 for all genes,
which indicates an overall low methylation status of CGIs
in promoter regions.
Figure 1: Up- vs. downregulated genes vs. whole
genome. Distribution of the average methylation status of
promoter-associated CpG sites in CGIs of upregulated and
downregulated genes over all age groups in different subsets
of genes. Tissue: whole blood. *** p<0.001.
Level of methylation in promoters associated to
long-lived people pre-exists at early stages of life
In the following, we investigated a possible correlation
between age and mean methylation status within the
promoters of the upregulated and downregulated genes
and the whole genome over the age. A small
but significant increase of the regression coefficient
was observed for all different subsets (Figure 2A,
Supplementary Information Table S3). The average
methylation status of the whole genome revealed the
highest coefficient (coeffGenome = 9.18 x 10−5 , p-value
= 2.34 x 10−9) and the highest R2-value of nearly 6
% over the age. However, the calculated values are
still small. The slope of the 25 upregulated genes
was 4.34 x 10−5 (p-value = 2.06 x 10−5 , significance
level = 0.05). The R2-value was equally significant
but relatively small at 2.74 %. Both values are rather
small: age accounts for only 2.74 % of the variance
of the average methylation status in the investigated
promoter regions. The regression coefficient of the
25 genes whose expression was lower in LLIs than in
younger individuals was 5.69 x 10−5 (p-value = 1.704 x
10−7), associated with a low R2-value of 0.041. This
is about double the value of the upregulated genes.
The comparison of the small gene subgroup with that
of all DEG showed that the upregulated genes of the
respective group revealed both a similar coefficient and
a similar R2-value. The same phenomenon could be
found in the downregulated genes. All the slopes are
very weak, which, however, strongly suggests that the
methylation of these genes changes very little over the
course of a lifetime.
Figure 2: (A) Average methylation status of
promoter-associated CpG sites of all different subsets
(e.g. legend). The lines show the regression coefficient. (B)
Means of the average methylation status of the 25 upregulated
(red) and the 25 downregulated (grey) genes in six different
age-intervals. *** p<0.001.
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As we could find the most significant difference
between the up- and downregulated genes in the second
subset, we used this group of 50 genes for further
analysis (Supplementary Table S3). Next, we wanted
to determine whether the average methylation of the 50
genes differs significantly when the 656 individuals were
clustered by age. Using a paired t-test, a significant
difference with p-values < 2.2 x 10−16 could be found
in all six age groups between the upregulated and the
downregulated genes (Figure 2B). In order to be able
to carry out a direct comparison of young and old
individuals later on the distribution of age groups was
chosen to be similar to those from the gene expression
analysis in [31]. To have a similar number of subjects
in all groups, the age intervals were divided as follows:
19-45 (similar to 20-55 in [31]), 46-55, 56-65, 66-75,
76-84 and 85-101 (similar to 90-104 in [31]). The mean
of the differences ranged from 0.042 (age: 85-101) and
0.044 (age: 19-45), whereby means of the upregulated
genes were higher in all age intervals. A t-test comparing
the average methylation status of the oldest group
(85-101 years) with the youngest group (19-45 years)
revealed a non significant difference for the upregulated
genes (p-value = 0.05826).
Methylation status of most up- or downregulated
genes related to LLIs does not change with age
The general model of gene regulation predicts
a negative correlation between levels of promoter
methylation and expression [36–38]. Results suggest
that age tends to be accompanied by site-specific
hypermethylation [39]. LLIs exhibit a different pattern
in this study: the methylation of promoters is found to
not correlate with expression and remains stable over
a person’s lifetime. This was confirmed by submitting
each gene to a linear regression (Table 1). Four
of the upregulated genes seem to indicate a slight
influence of methylation on gene expression, when
the average methylation status across CpGs over age
is analysed: POLB (Figure 3A), SLC27A3, TRIP4,
and DNAJC1. These significant regression coefficients
were negative, in association with age (Table 1). In
addition, among the genes with a significant regression
coefficient, the proportion of hypomethylated properties
(decreasing methylation with increasing age) was larger
in the upregulated genes than in downregulated genes
(Table 1). This suggests that the expression of
such highly expressed genes is partially influenced
by the decreasing DNA methylation which occurs with
age. All downregulated genes with a significant
coefficient exhibited increasing methylation with age,
except for one, NIPAL3 (Figure 3C). Otherwise, the
change corresponds to their expression profile, since the
expression of a gene is more likely to be lower when
the CGIs of the promoter are more highly methylated.
Nevertheless, in every investigated case, the R2-value
was very low. This represents the degree to which
the methylation status can be explained by age. The
significant regression coefficient of the genes, however,
with a value close to zero corresponds to the model
of increasing methylation by age. The low R2-value
indicates that other factors beyond DNA methylation play
a role in the regulation of gene expression during aging
as well.
Figure 3: Genes with the highest and lowest slope value.
(A) shows the lowest coefficient and (B) the highest coefficient
of the upregulated genes during aging. (C) displays the lowest
and (D) the highest slope of the downregulated genes.
DISCUSSION
In this study we present hints showing that the
promoters of genes which are highly expressed in aging
people exhibit comparatively high levels of methylation
already present in earlier stage of life. Usually,
highly methylated CGIs in promoters are assumed
to represent gene silencing. Nevertheless, if gene
expression in aging people increases or decreases
while the methylation status remains more or less the
same, this can probably be ascribed to other epigenetic
mechanisms that come into play and suppress the
normal effects of DNA methylation. At some point
over a lifetime, methylation levels no longer suffice to
regulate the levels of the expression of certain genes.
The role of epigenetic mechanisms participating in
this process is currently unclear. As a result, genes
can be differentially expressed despite a comparable
degree of DNA methylation status, and that the genes
already expressed at low levels are impaired by lowering
expression even further.
Ideally, data on methylation and expression over the
course of aging could be investigated for the same
individuals. To our knowledge, however, those data are
not available. In the future, it would be very interesting
to generate a methylation data set and the respective
gene expression profiles in a group of people over 85
years of age, and to compare the results with similar data
from 60-80-year-old individuals, which would produce
more clear result in specific real differences. Here, we
provide a first indication that aging people experience a
repression of gene expression regulation through DNA
methylation over their lifetimes, which may be the result
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of epigenetic mechanisms and other factors beyond
DNA methylation in promoter-associated CpG islands.
The next steps should be integrating data regarding
the activity of other epigenetic mechanisms to obtain
a more comprehensive view of the regulation of genes
related to longevity. Other epigenetic mechanisms
have been shown to undergo changes that influence
gene expression patterns over the course of aging
or in relation to longevity [40]. One example is a
general loss of histones that comes with age and
decreases the stability of the genome [40, 41]. The
best strategy to determine how these factors combine to
influence genes which are highly expressed in long-lived
individuals would be to launch a large QTL study in
which many types of epigenetic data, including histone
modifications, DNA methylation, histone concentrations
and other mechanisms would be considered in parallel
in the same subjects. This would provide invaluable
data toward understanding how the many changes that
cells experience over time interact with each other in
promoting health into the last years of our lives.
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